Newer Targets

Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS...

Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 - FirstWord Pharma

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis...

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection - FirstWord Pharma

Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights...

Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights Nasdaq:ASMB

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Nasdaq:CYCC

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Nasdaq:CYCC

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel...

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform
- Advertisement -

LATEST NEWS

MUST READ